Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime

Annals of the Academy of Medicine Singapore

Volumn 37, Issue 11, 2008, Pages 916-918

  Sadeghian, Giti ^a   Ziaei, Hengameh ^b   Sadeghi, Masumeh ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antimonial compound; Cardiac monitoring; Toxicity

Indexed keywords

MEGLUMINE ANTIMONATE;

ADULT; ARTICLE; BRADYCARDIA; CARDIOVASCULAR RISK; DRUG EFFECT; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART LEFT BUNDLE BRANCH BLOCK; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MAJOR CLINICAL STUDY; MALE; QT PROLONGATION; SIDE EFFECT; SKIN LEISHMANIASIS; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; SUPRAVENTRICULAR PREMATURE BEAT; T WAVE; TACHYCARDIA;

EID: 57649210794     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. KiKuth W, Schmidt H. Contribution to the progress of antimony therapy of Kala-azar. Chinese Med J 1937;52:425-32.
2. Durand P, Benmussa S, Caruana M. Traitment du Kala-Azar par un nouveau campose stibie:2, 168 RP (Premiers resultats). Bull Mem soe med Bop Paris 1946;62:399-409.
3. Ribeiro ALP, Drummond JB, Volpini AC, Andrade AC, Passos VMA. Electrocardiograpfic changes during low-dose, short-term therapy of cataneous leishmaniasis with pentavalent antimonial meglumine. Braz J Med Biol Res 1999;32:297-301.
4. Voller A, shaw JJ, Bryant C. The effects of two antimony drugs on the in vitro metabolitm of radioactive glucose forms of leishmania tropica. Ann Trop Med Parasitol 1963;57:404-8.
5. Berman JD, Waddell D, Hanson BC. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother 1985;27:916-20.
6. Berman JD, Wyler DJ. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis 1980;142:83-6.
7. Chulay JD, Spencer HG, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibugluconate). Am J Trop Med 1985;34:702-9.
8. Ethan A, Lerner A, Suzanne A. Leiashmaniasis. In: Arndt KA, Leboit PE, Rohinson JK, Wntroub BU, editors. Cutaneous Medicine and Surgery. Plc of publication?: WB Saunders 1996;126:1163-70.
9. Josephson ME, Zimetbaum P. The bradyarrhythmias: disorders of sinus node function and AV conduction disturbances. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw Hill, 2005:1333-42.
10. Chulay JD, Anzana EM, Koech DK, Bryceson AD. High dose sodium stibogloconate treatment of cutaneous leishmaniasis in Kenya. Trans R Soc Trop Med Hyg 1983;77:712-21.
11. Thakur CP, Sinha GP, Pandey AK, Kumar N, Hassan SM, Narain S, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in BiharIndia, justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol 1998;92:561-9.
12. Antezana Zeballos R, Mendoza C, Lyevre P, Valda L, Cardenas F, Noriega I, et al. Electrocardiographic alternations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and alloporinol. Trans R Soc Trop Med Hyg 1992;86:31-3.
13. Berhe N, Abraham Y, Hailu A, Ali A, Mengistu G, Tsige K, et al. Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasis. East Afr Med J 2001;78:608-10.